13.62
price down icon7.47%   -1.10
after-market After Hours: 13.63 0.01 +0.07%
loading
Iovance Biotherapeutics Inc stock is traded at $13.62, with a volume of 12.15M. It is down -7.47% in the last 24 hours and up +37.99% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$14.72
Open:
$14.65
24h Volume:
12.15M
Relative Volume:
0.92
Market Cap:
$6.17B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-14.34
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
-6.84%
1M Performance:
+37.99%
6M Performance:
+258.42%
1Y Performance:
+508.04%
1-Day Range:
Value
$13.52
$14.71
1-Week Range:
Value
$13.52
$14.82
52-Week Range:
Value
$1.76
$15.30

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Name
Iovance Biotherapeutics Inc
Name
Phone
(650) 260-7120
Name
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Employee
975
Name
Twitter
Name
Next Earnings Date
2026-11-05
Name
Latest SEC Filings
Name
IOVA's Discussions on Twitter

Compare IOVA vs VRTX, MRNA, REGN, ARGX, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IOVA icon
IOVA
Iovance Biotherapeutics Inc
13.62 6.17B 285.55M -353.86M -305.02M -0.9501
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-24-26 Resumed Goldman Buy
Feb-25-26 Upgrade Citizens Mkt Perform → Mkt Outperform
Jul-15-25 Downgrade Goldman Neutral → Sell
May-16-25 Downgrade UBS Buy → Neutral
May-12-25 Downgrade Truist Buy → Hold
May-09-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS Buy
Jul-29-24 Downgrade Piper Sandler Overweight → Neutral
Nov-20-23 Initiated Goldman Buy
Sep-18-23 Reiterated Barclays Overweight
May-30-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-27-23 Upgrade Piper Sandler Neutral → Overweight
Dec-09-22 Downgrade Goldman Buy → Neutral
Oct-31-22 Initiated Guggenheim Neutral
Aug-18-22 Resumed Wells Fargo Equal Weight
Jan-28-22 Upgrade Stifel Hold → Buy
Dec-07-21 Resumed Cowen Outperform
Jun-10-21 Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-20-21 Downgrade Piper Sandler Overweight → Neutral
May-19-21 Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-19-21 Downgrade Stifel Buy → Hold
May-03-21 Initiated Truist Buy
Apr-16-21 Initiated Goldman Buy
Mar-08-21 Upgrade H.C. Wainwright Neutral → Buy
Dec-15-20 Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20 Initiated Mizuho Buy
Mar-04-20 Initiated Barclays Overweight
Feb-26-20 Reiterated H.C. Wainwright Buy
Feb-26-20 Reiterated Oppenheimer Outperform
Dec-18-19 Initiated JMP Securities Mkt Outperform
Oct-01-19 Initiated Stifel Buy
Apr-29-19 Initiated Piper Jaffray Overweight
Feb-28-19 Reiterated Chardan Capital Markets Buy
Feb-07-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy
Jul-06-18 Reiterated Chardan Capital Markets Buy
Apr-10-18 Upgrade B. Riley FBR, Inc. Neutral → Buy
Mar-13-18 Reiterated B. Riley FBR, Inc. Neutral
Feb-23-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Jan-25-18 Reiterated H.C. Wainwright Buy
Nov-01-17 Reiterated B. Riley FBR, Inc. Buy
View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

pulisher
Oct 09, 2026

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 04, 2026

Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 04, 2026
pulisher
Oct 02, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 02, 2026
pulisher
Oct 02, 2026

Iovance Biotherapeutics (LSE:0JDK) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 02, 2026
pulisher
Oct 01, 2026

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - The Manila Times

Oct 01, 2026
pulisher
Oct 01, 2026

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.

Oct 01, 2026
pulisher
Oct 01, 2026

Iovance's new medical chief led programs that helped drive a drug above $2 billion in annual sales. - Stock Titan

Oct 01, 2026
pulisher
Sep 30, 2026

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research

Sep 30, 2026
pulisher
Sep 30, 2026

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Zacks Investment Research

Sep 30, 2026
pulisher
Sep 30, 2026

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 30, 2026
pulisher
Sep 21, 2026

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research

Sep 21, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Sep 18, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Moomoo

Sep 18, 2026
pulisher
Sep 10, 2026

Iovance Biotherapeutics' Chief Regulatory Officer Reports RSU Vesting and Tax Withholding Transactions - Kalkine Media

Sep 10, 2026
pulisher
Sep 10, 2026

Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com Australia

Sep 10, 2026
pulisher
Sep 10, 2026

Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com UK

Sep 10, 2026
pulisher
Sep 09, 2026

Iovance Biotherapeutics (IOVA) Institutional Ownership 2026 - MarketBeat

Sep 09, 2026
pulisher
Sep 08, 2026

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - Stocktwits

Sep 08, 2026
pulisher
Sep 06, 2026

How Iovance Biotherapeutics Inc. (IOVA) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 06, 2026
pulisher
Sep 04, 2026

Iovance Biotherapeutics, Inc. (IOVA) Latest Press Releases & Corporate News - Yahoo Finance

Sep 04, 2026
pulisher
Sep 04, 2026

Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewswire

Sep 04, 2026
pulisher
Sep 03, 2026

NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 03, 2026
pulisher
Sep 01, 2026

Iovance Biotherapeutics (IOVA) Stands Out with Strong Quant Rati - GuruFocus

Sep 01, 2026
pulisher
Aug 29, 2026

Iovance Biotherapeutics (IOVA) Wins FDA Trial Clearance, Is The Stock Still 54% Undervalued? - sahmcapital.com

Aug 29, 2026
pulisher
Aug 27, 2026

Iovance Biotherapeutics Inc. (IOVA) Peer Comparison – Compare with Others - Value Research

Aug 27, 2026
pulisher
Aug 27, 2026

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress

Aug 27, 2026
pulisher
Aug 22, 2026

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress

Aug 22, 2026
pulisher
Aug 21, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Aug 21, 2026
pulisher
Aug 21, 2026

Biotech company Iovance grants 20 new employees options with an $8.99 exercise price - Stock Titan

Aug 21, 2026
pulisher
Aug 21, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8%Here's Why - MarketBeat

Aug 21, 2026
pulisher
Aug 21, 2026

IOVA Stock Pulls Back As Biotech Momentum Cools - StocksToTrade

Aug 21, 2026
pulisher
Aug 21, 2026

UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations - TIKR.com

Aug 21, 2026
pulisher
Aug 21, 2026

Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? - Benzinga

Aug 21, 2026
pulisher
Aug 20, 2026

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - TradingView

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics grants inducement stock options to 27 new employees - scanx.trade

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Shares Rise 12.5% as Analyst Price Targets Lag Behind Rally - TechStock²

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics stock trends on sector momentum, Q2 beat - scanx.trade

Aug 20, 2026
pulisher
Aug 20, 2026

Why Iovance Biotherapeutics Stock Hit 52-Week High - TradingView

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Maintained by UBS -- Price Target Raised to $7.00 - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says - marketscreener.com

Aug 20, 2026
pulisher
Aug 20, 2026

META_TITLE_QUOTE - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Stock Climbs As Earnings Beat Fuels Guidance Rethink - StocksToTrade

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Marks Major Market Shift - Kalkine Media

Aug 20, 2026
pulisher
Aug 20, 2026

Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates (IOVA) - Seeking Alpha

Aug 20, 2026
pulisher
Aug 20, 2026

UBS raises Iovance Biotherapeutics stock price target on revenue beat By Investing.com - Investing.com Canada

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month HighWhat's Next? - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

IOVANCE BIOTHERAPEUTICS INC : UBS RAISES TARGET PRICE TO $7 FROM $4 - webull.com

Aug 20, 2026

Iovance Biotherapeutics Inc Stock (IOVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
BILINSKY IGOR
Chief Operating Officer
Sep 08 '26
Option Exercise
0.00
7,813
0
146,050
Puri Raj K.
Chief Regulatory Officer
Sep 08 '26
Option Exercise
0.00
9,766
0
260,842
Vogt Frederick G
Interim CEO & General Counsel
Sep 01 '26
Option Exercise
0.00
41,669
0
604,161
Puri Raj K.
Chief Regulatory Officer
Sep 01 '26
Option Exercise
0.00
5,470
0
253,584
BILINSKY IGOR
Chief Operating Officer
Sep 01 '26
Option Exercise
0.00
8,789
0
142,709
Kirby Daniel Gordon
Chief Commercial Officer
Aug 10 '26
Option Exercise
0.00
10,001
0
156,947
Roche Corleen M.
Chief Financial Officer
Aug 06 '26
Option Exercise
0.00
49,995
0
49,995
Vogt Frederick G
Interim CEO & General Counsel
Jun 05 '26
Option Exercise
0.00
15,625
0
569,130
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Jun 05 '26
Option Exercise
0.00
7,813
0
144,087
Puri Raj K.
Chief Regulatory Officer
Jun 05 '26
Option Exercise
0.00
9,766
0
251,957
$86.17
price down icon 2.05%
$295.54
price down icon 0.99%
$142.78
price down icon 6.45%
$241.76
price down icon 2.61%
$26.73
price down icon 2.84%
KOD KOD
$85.75
price down icon 2.69%
Cap:     |  Volume (24h):